tech
Reid Hoffman says the next AI gold rush is in medicine
The LinkedIn and Manas AI cofounder said there's a lot of money to be made for companies using AI to accelerate drug discovery and development.
TL;DR
- Reid Hoffman identifies AI in medicine as a major potential revenue opportunity, surpassing the AI chatbot market.
- He believes companies are overlooking the massive total addressable market (TAM) in medicine.
- Hoffman co-founded Manas AI, a biopharmaceutical company using AI to discover and bring medicines to market more efficiently.
- Manas AI aims to create a 'drug discovery factory' by using AI to bolster early-stage research.
- Drug patents offer 20-year monopolies, with additional market exclusivity periods for certain drugs.
- The biopharmaceutical space has seen a rise in AI startups since the COVID-19 pandemic.
- Hoffman disagrees with the 'winner-take-all' market theory, citing multiple successful providers of GLP1 drugs.